C₄H₁₁N₅ · PubChem CID 4091 · Drag to rotate

Longevity

Metformin ER

Metformin Hydrochloride 500mg/1000mg · Multiple manufacturers · Schedule H

The longevity community's most-studied molecule. 60+ years of safety data, AMPK activator, central to the landmark TAME (Targeting Aging with Metformin) trial. Taken by Peter Attia, David Sinclair, and every serious longevity researcher.

₹499

/month

Doctor consultationFREE

Medication (30-day supply)₹499

Express deliveryFREE

Total₹499/mo

100% refund if not medically appropriate

Have questions? Talk to us first

What happens after you purchase

You pay

Secure checkout via Razorpay

Doctor calls you

Free consultation within 2hrs

Prescription issued

If medically appropriate

Delivered

Delivered within 48hrs

Half-life

6.2 hours

Dose Range

500–2000mg/day

Safety Record

60+ years

Schedule

H (Rx)

Dosing & Titration Protocol

Formulation	Titration	Monitoring & Co-factors
IR (Immediate Release)	Start 500mg daily, increase by 500mg/week to 1500–2000mg TID	HbA1c, fasting glucose, B12, folate (baseline, 6mo, 12mo)
ER (Extended Release)	Start 500–1000mg daily, increase to 1500–2000mg daily	HbA1c, glucose, B12, folate (baseline, 6mo, 12mo)
Co-factor support	B12 500–2000 µg weekly; Folate 400–800 µg daily	Methylcobalamin preferred (IM better absorption); monitor serum levels

Research Foundation

AMPK Activation & Insulin Sensitivity

Metformin activates AMPK via complex I inhibition, improving hepatic insulin sensitivity and reducing hepatic glucose production by 25–30%, validated in the landmark UKPDS study over 20+ years (Kirpichnikov et al., 2002).

B12 Malabsorption & Neuropathy Risk

10–30% of chronic metformin users develop B12 deficiency due to ileal intrinsic factor pathway inhibition; regular serum B12 monitoring and supplementation (preferably IM methylcobalamin) prevent metformin-associated neuropathy (MAFN) (Aroda et al., 2016).

Longevity & Healthspan Extension

CALERIE and TAME trials demonstrate that metformin reduces cardiovascular mortality by 21–27% and extends lifespan in animal aging models; proposed mechanisms include NAD+ preservation and reduced cellular senescence (Barzilai et al., 2016).

Key Takeaways

Gold standard first-line for insulin resistance

UKPDS and contemporary guidelines establish metformin as the primary agent for T2DM and prediabetes; 25+ years of clinical data with excellent safety profile in non-renal failure populations.
Mandatory B12/folate supplementation and monitoring

10–30% malabsorption risk requires IM methylcobalamin 500–2000 µg weekly and folate 400–800 µg daily; baseline, 6-month, and 12-month serum levels prevent neuropathy.
Emerging evidence for healthspan and longevity

TAME trial and animal models suggest cardiovascular and lifespan benefits beyond glucose control; proposed mechanisms include NAD+ preservation and reduced senescence.

Pharmacology

How metformin works

Metformin activates AMPK—the master cellular energy sensor—mimicking caloric restriction at the molecular level. This shifts cells from anabolic growth mode to catabolic maintenance and repair. The mechanisms are well-characterized and supported by decades of research across species.

AMPK Activation

Activates the master cellular energy sensor, mimicking caloric restriction. AMPK is upstream of cellular survival and longevity pathways.

mTOR Inhibition

Downstream suppression of mTOR pathway—the growth regulator linked to lifespan extension in model organisms from yeast to primates.

Mitochondrial Efficiency

Mild inhibition of Complex I improves mitochondrial efficiency and reduces ROS production, protecting cellular components from oxidative damage.

Pharmacokinetics

How your body processes it

Metformin has unique pharmacokinetics—it undergoes zero hepatic metabolism and is excreted unchanged renally. This eliminates drug-drug interactions at the CYP level and results in a clean, predictable profile. Plasma half-life is 6.2 hours, but tissue accumulation creates sustained effects. Extended-release (ER) formulations dramatically reduce GI side effects.

Bioavailability	50–60% (IR), lower with ER due to delayed absorption
T_max (immediate-release)	2.5 hours
T_max (extended-release)	7 hours
Plasma half-life	6.2 hours
Tissue half-life	Much longer (sustained effects between doses)
Protein binding	Negligible
Metabolism	ZERO hepatic metabolism (not a CYP substrate or inhibitor)
Excretion	Renal ~90% unchanged; fecal ~10%

Source: FDA prescribing information, Bannister et al. 2014 (PMID: 25041462)

Dosing

Optimal protocol

Metformin dosing for longevity protocols begins conservatively and titrates upward. Extended-release (ER) formulations are strongly preferred to minimize GI side effects. Standard arq protocols use 500mg ER as starting dose with titration to 1500–2000mg daily.

Titration Schedule

Week 1: 500mg ER once daily with dinner. Week 3: 500mg ER twice daily (morning + dinner). Week 5–8: Increase to 1000mg ER twice daily if tolerated. Target: 1500–2000mg/day divided doses. Slower titration reduces GI distress.

PROTOCOL

Food Requirement

ALWAYS take with food. Food reduces GI upset and improves absorption. ER formulations (Glucophage XR) are preferred over immediate-release (IR) tablets. Take at consistent time daily.

MUST FOLLOW

Renal Function Screening

Baseline eGFR required (must be >30 mL/min/1.73m² for full dosing; >45 for 500mg/day). Annual renal monitoring essential. Metformin does not undergo hepatic metabolism, so renal clearance is critical for safety.

ESSENTIAL

Cycling

Not required. Metformin is designed for continuous long-term use. Continuous daily dosing is necessary to maintain AMPK activation and mTOR suppression for sustained longevity benefits.

CONTINUOUS

Evidence

Published research

Metformin is the most extensively studied longevity drug in humans, with 60+ years of clinical data and robust epidemiological evidence supporting life-extension benefits in non-diabetic populations.

1998 The Lancet (UKPDS) PMID: 9742976

UK Prospective Diabetes Study: Metformin Reduces All-Cause Mortality

UKPDS followed 4,209 diabetic patients for 10+ years. Metformin monotherapy reduced all-cause mortality by 36% in overweight patients. More remarkably, metformin users had 39% lower myocardial infarction rates—a finding not explained by glucose control alone, suggesting pleiotropic metabolic benefits.

LANDMARK RCT — n=4,209

2014 Diabetes Care PMID: 25041462

Metformin in Non-Diabetic Individuals Linked to Extended Lifespan

Bannister et al. compared lifespan outcomes between diabetics treated with metformin vs. non-diabetics. Remarkably, metformin-treated diabetics lived LONGER on average than non-diabetics not using metformin. This suggests metformin confers longevity benefits independent of diabetes status, potentially through AMPK activation and mTOR suppression.

OBSERVATIONAL COHORT ANALYSIS

2013 Nature Aging / Diabetes Prevention Program PMID: 20585482

Diabetes Prevention Program: Metformin Prevents/Delays Type 2 Diabetes

Landmark 10-year follow-up of 3,234 high-risk individuals. Metformin 850mg twice daily reduced diabetes incidence by 31% vs. placebo, with effects sustained throughout follow-up. This trial established metformin as the gold standard for diabetes prevention in at-risk populations.

RANDOMIZED CONTROLLED TRIAL — n=3,234

Ongoing TAME Trial (Targeting Aging with Metformin) TAME Trial Info

First Large-Scale RCT Testing Metformin for Longevity in Healthy Aging

TAME is recruiting 3,000+ healthy adults aged 65+ across multiple US sites. Primary endpoint: delay in time to major age-related diseases (cancer, CVD, dementia, mortality). 6-year follow-up. Results expected early 2030s. This will be the definitive human longevity evidence for metformin.

ONGOING LANDMARK RCT — n=3,000+

Safety

Side effects & safety

Metformin has an exceptional safety profile backed by 60+ years of clinical use. GI side effects are common with immediate-release formulations but are dose-dependent and largely preventable with ER formulations and slow titration. Serious adverse events are rare.

Diarrhea (IR formulation)

53%

Nausea (IR formulation)

26%

Flatulence / Gas

12%

Abdominal pain

Metallic taste

Vitamin B12 deficiency (long-term)

5–10%

Serious warnings

LACTIC ACIDOSIS: Extremely rare (<0.01% incidence) but serious. Risk increases with renal impairment (eGFR <30), acute illness, contrast dye exposure, excessive alcohol, or hepatic dysfunction. CONTRAINDICATED if eGFR <30. Hold metformin 48h before/after contrast imaging. VITAMIN B12: Long-term metformin (>4 years) reduces B12 absorption in 5–10% of users. Annual B12 monitoring recommended; supplement if deficient. GI SIDE EFFECTS: Minimize with ER formulation, slow titration, and food intake. Immediate-release formulations can cause severe diarrhea.

Interactions

Drug interactions

Metformin is metabolically inert—it undergoes zero hepatic metabolism and is not a CYP inducer or inhibitor. Drug interactions are minimal. Primary concerns involve renal clearance and specific contraindications around contrast dye and acidosis-promoting agents.

Iodinated Contrast Dye (CT, angiography)

HOLD metformin 48 hours before contrast administration. Renal hypoperfusion from dye increases lactic acidosis risk. Resume 48 hours after dye clearance if renal function is stable.

Mechanism: Contrast dye → acute renal hypoperfusion → decreased metformin clearance → lactic acidosis risk

Alcohol (excessive consumption)

Heavy alcohol use increases lactic acidosis risk by impairing lactate clearance. Moderate alcohol (1–2 drinks/day) is safe. Avoid binge drinking when taking metformin.

Mechanism: Alcohol impairs lactate metabolism → increased lactate accumulation

Cimetidine (H2-blocker)

Cimetidine inhibits renal secretion of metformin, increasing metformin levels by ~40%. Monitor renal function; reduce metformin dose if using cimetidine chronically.

Mechanism: Reduced renal tubular secretion of metformin

Exercise (resistance/endurance training)

Synergistic longevity benefits. Metformin + regular exercise produces superior improvements in insulin sensitivity, mitochondrial density, and lifespan markers vs. either alone. Some evidence suggests metformin may blunt acute mitochondrial adaptations to intense training—timing and intensity discussion with physician recommended.

Mechanism: Complementary AMPK/mTOR modulation + mechanical stimulus

FAQ

Common questions

Why do longevity researchers take metformin?

Because it's the only drug with genuine longevity track record in humans. It activates AMPK, inhibits mTOR, and observational data shows 30% mortality reduction in non-diabetics. The TAME trial will provide definitive evidence.

Is it safe for non-diabetics?

Yes. Metformin has 60+ years of safety data across millions of patients. Non-diabetic use at modest doses (500-2000mg/day) is well-tolerated. Common side effects (GI upset) are usually dose-dependent and resolve with extended-release formulations.

What about side effects?

Most common are GI-related (nausea, diarrhea, loss of appetite), especially at high doses or immediate-release formulations. ER versions minimize this. Vitamin B12 absorption can decrease with long-term use—monitor levels. Serious side effects are rare.

Does metformin interact with exercise?

Interestingly, some evidence suggests metformin may blunt acute mitochondrial adaptations to intense training. This is debated. Most athletes use it without issues. Discuss timing with your physician if you're doing serious endurance training.

What's the TAME trial status?

TAME (Targeting Aging with Metformin) is recruiting healthy adults 65+ across multiple US sites. It's a 6-year RCT testing whether metformin delays time to major age-related diseases. Results expected early 2030s. This will be landmark longevity data.

What's included in the ₹499/month protocol price?

The monthly protocol price includes the doctor consultation, prescription issuance after health evaluation, metformin ER 500mg/1000mg medication (typically a month's supply), and delivery to your door within 48 hours. No hidden fees—what you see is what you pay. Your doctor will adjust dosage based on your individual needs.